arrow left
arrow right
  • Cresco Labs New York, Llc, a New York limited liability company, Cresco Labs Llc, An Illinois Limited Liability Company v. Fiorello Pharmaceuticals, Inc., a New York corporation, Eric Sirota, Susan Yoss, John Does 1 - 10 Commercial Division document preview
  • Cresco Labs New York, Llc, a New York limited liability company, Cresco Labs Llc, An Illinois Limited Liability Company v. Fiorello Pharmaceuticals, Inc., a New York corporation, Eric Sirota, Susan Yoss, John Does 1 - 10 Commercial Division document preview
  • Cresco Labs New York, Llc, a New York limited liability company, Cresco Labs Llc, An Illinois Limited Liability Company v. Fiorello Pharmaceuticals, Inc., a New York corporation, Eric Sirota, Susan Yoss, John Does 1 - 10 Commercial Division document preview
  • Cresco Labs New York, Llc, a New York limited liability company, Cresco Labs Llc, An Illinois Limited Liability Company v. Fiorello Pharmaceuticals, Inc., a New York corporation, Eric Sirota, Susan Yoss, John Does 1 - 10 Commercial Division document preview
  • Cresco Labs New York, Llc, a New York limited liability company, Cresco Labs Llc, An Illinois Limited Liability Company v. Fiorello Pharmaceuticals, Inc., a New York corporation, Eric Sirota, Susan Yoss, John Does 1 - 10 Commercial Division document preview
  • Cresco Labs New York, Llc, a New York limited liability company, Cresco Labs Llc, An Illinois Limited Liability Company v. Fiorello Pharmaceuticals, Inc., a New York corporation, Eric Sirota, Susan Yoss, John Does 1 - 10 Commercial Division document preview
						
                                

Preview

FILED: NEW YORK COUNTY CLERK 01/19/2022 06:42 PM INDEX NO. 652343/2018 NYSCEF DOC. NO. 588 RECEIVED NYSCEF: 01/19/2022 EXHIBIT 29 March 19, 2018 email from Cresco’s counsel to Fiorello’s counsel with a list of outstanding due diligence items Index No. 652343/2018 FILED: NEW YORK COUNTY CLERK 01/19/2022 06:42 PM INDEX NO. 652343/2018 NYSCEF DOC. NO. 588 RECEIVED NYSCEF: 01/19/2022 From: Christopher R. Walker Sent: Monday, March 19, 2018 9:12 AM CDT To: slinsky@lucbro.com CC: Katherine B. Lewis; Bob Morgan Subject: Revised Legal Due Diligence Request List Related to the Acquisition of Fiorello Pharmaceuticals, Inc. [IWOV- MS1.FID499011] Attachments: Cresco Labs New York - Due Diligence Request List - Fiorello Pharmaceuticals(dto)(19 Mar 2018).DOCX Scott, Please find attached the Revised Legal Due Diligence Request List Related to the Acquisition of Fiorello Pharmaceuticals, Inc. In most cases, we simply want to confirm that the information provided is complete, and that we have seen all of the documents that are responsive to each request. We are happy to schedule a short call to walk through the list. In particular, a few items remain outstanding:  We have not seen stock certificates for each of the stock holders (please provide);  We need an example waterfall, indicating with specificity the equity holders, the amount of equity held by each equity holder, and the exact amount of consideration that each equityholder should expect to receive (please provide);  The WeWork agreement appears to only be terminable 12 months after moving into an expanded office space (please provide your thoughts and any suggestions regarding resolution); and  We need to confirm the cancelation or termination of all consulting agreements (please provide). Best regards, Christopher R. Walker Christopher R. Walker Much Shelist, P.C. 191 North Wacker Drive, Suite 1800 Chicago, IL 60606 Phone 312.521.2786 Fax 312.521.2886 cwalker@muchshelist.com Visit our website at www.muchshelist.com Member of Ally Law Please consider the environment before printing this email. The information contained in this email communication is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the MS_000397 FILED: NEW YORK COUNTY CLERK 01/19/2022 06:42 PM INDEX NO. 652343/2018 NYSCEF DOC. NO. 588 RECEIVED NYSCEF: 01/19/2022 reader of this message is not the intended recipient, you are hereby notified that you have received this communication in error, and that any review, dissemination, distribution, or copying of the message is strictly prohibited. If you have received this transmission in error, please notify us immediately by telephone and/or reply email. MS_000398